Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by daclatasvir and asunaprevir combination therapy in genotype 1 HCV-infected hemodialysis patients
Not Applicable
- Conditions
- genotype 1 HCV patients receiving hemodialysis
- Registration Number
- JPRN-UMIN000024261
- Lead Sponsor
- Department of Gastroenterology and Hepatology, Tokai University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with decompensated cirrhosis 2)Patients complicated with hepatic cancer 3)Other patients whom the chief investigator or a sub-investigators considers inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare erythropoietic resistance index change between pre and post of treatment in the early intervention group and waiting intervention group
- Secondary Outcome Measures
Name Time Method To assess Iron metabolism kinetics To assess mineral-bone metabolism kinetics To assess antiviral activity, the proportion of subjects who achieve undetectable HCV RNA at post treatment week 12 To assess safety To assess CLDQ-HCV, KDQOL-SF